Butorphanol
Revision as of 23:03, 26 January 2019 by ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: synthetic mixed agonist-antagonist opioid *Dosage Forms: *Routes of Administration: IV, IN *Common Trade Names: ==Adult Dosing== *0.5-2mg IV, I...")
Administration
- Type: synthetic mixed agonist-antagonist opioid
- Dosage Forms:
- Routes of Administration: IV, IN
- Common Trade Names:
Adult Dosing
- 0.5-2mg IV, IM, or IN q3h prn
Pediatric Dosing
Special Populations
Pregnancy Rating
- Category C
Lactation risk
- Infant risk cannot be ruled out
Renal Dosing
- Reduce dose (0.5-1mg)
Hepatic Dosing
- Reduce dose (0.5-1mg)
Contraindications
- Allergy to class/drug
- Significant respiratory depression
- Acute or severe asthma if unmonitored setting
- Known or suspected SBO or ileus
Adverse Reactions
Serious
- Respiratory depression
Common
- Nausea/vomiting
- Sedation/somnolence, Dizziness, insomnia
- Nasal congestion (long term use of IN)
Pharmacology
- Half-life: 4-6h in healthy patients, 10-17h inhepatic or renal impairment
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Mixed agonist-antagonist analgesic, kappa-opioid receptor agonist, low intrinsic activity at mu-opioid receptor